Overview

A Study of LY3200882 in Participants With Solid Tumors

Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
0
Participant gender:
All
Summary
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Gemcitabine
Paclitaxel
Criteria
Inclusion Criteria:

- The participant must have histological or cytological evidence of cancer.

- Have adequate organ function.

- Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.

- Are able to swallow capsules and tablets.

Exclusion Criteria:

- Have moderate or severe cardiovascular disease.

- Have a serious concomitant systemic disorder.

- Have acute leukemia.